FY2025 Earnings Estimate for MCRB Issued By Chardan Capital

Seres Therapeutics, Inc. (NASDAQ:MCRB) – Analysts at Chardan Capital increased their FY2025 earnings per share (EPS) estimates for Seres Therapeutics in a research note issued on Monday, March 24th. Chardan Capital analyst K. Nakae now forecasts that the biotechnology company will earn ($0.57) per share for the year, up from their prior estimate of ($0.73). Chardan Capital currently has a “Buy” rating and a $1.25 target price on the stock. The consensus estimate for Seres Therapeutics’ current full-year earnings is ($0.38) per share.

Several other equities research analysts also recently weighed in on the company. StockNews.com raised Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, March 6th. The Goldman Sachs Group lowered their target price on shares of Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating for the company in a research note on Friday, March 14th. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.00.

Seres Therapeutics Price Performance

Shares of MCRB stock opened at $0.73 on Thursday. The stock’s fifty day moving average price is $0.78 and its 200 day moving average price is $0.83. Seres Therapeutics has a 1-year low of $0.54 and a 1-year high of $1.53. The company has a market cap of $127.28 million, a price-to-earnings ratio of -3.17 and a beta of 2.19.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MCRB. FMR LLC increased its stake in shares of Seres Therapeutics by 0.6% in the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after acquiring an additional 140,096 shares during the period. Millennium Management LLC boosted its holdings in Seres Therapeutics by 77.2% in the fourth quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company’s stock valued at $1,505,000 after purchasing an additional 788,762 shares during the last quarter. Geode Capital Management LLC grew its position in Seres Therapeutics by 8.8% during the 4th quarter. Geode Capital Management LLC now owns 1,510,432 shares of the biotechnology company’s stock worth $1,256,000 after purchasing an additional 121,793 shares during the period. Vontobel Holding Ltd. raised its stake in shares of Seres Therapeutics by 137.6% during the 4th quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company’s stock valued at $780,000 after buying an additional 543,469 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Seres Therapeutics by 15.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company’s stock valued at $720,000 after buying an additional 117,107 shares during the period. 59.34% of the stock is currently owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.